ClinicalTrials.gg
RecruitingNCT06832839Updated Feb 18, 2025

Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease

An observational study in Moyamoya Disease, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-18.

Sponsored by Beijing Tiantan Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
360
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Moyamoya Disease by Beijing Tiantan Hospital — 10 open to participants now, 10 under way, none of them phase 3. Moyamoya Disease · Beijing Tiantan Hospital.

Planned enrollment
5th of 11
360 · median 350
Started
2024
with 2 others
Observational
11 of 14
8 open now
Registered
9th of 14
by date

Among the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital, this one is the 5th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2024, is one of 11 observational ones, and was the 9th registered.

Moyamoya Disease

62 studies on the registry are indexed under Moyamoya Disease; 30 are open to participants now.

Browse Moyamoya Disease studies →

Open to participants now

10 of the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 22 Moyamoya Disease studies recruiting now, 9 (41%) set no upper age limit and 10 (45%) stop at 75 or younger; 9 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Moyamoya Disease by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

The purpose of this study is to comprehensively evaluate the risk factors for cognitive decline in patients with moyamoya disease, identify imaging target areas associated with cognitive damage in the brain, and explore the changes in brain structure and functional networks resulting from cerebral revascularization, as well as their relationship with cognitive improvement.

Read the detailed description

Moyamoya disease (MMD) is a chronic occlusive-stenosis cerebrovascular disease that characterized by the stenosis of internal carotid artery termination and the formation of net-like vessel. It is a multifactorial disease caused by genetic, inflammatory, immunological and other environmental factors. The specific pathogenesis of MMD is still unclear. The treatment modalities of revascularization and conservative management have been used in patients with MMD. Due to the long-term low perfusion state of brain tissue, most patients with MMD experience varying degrees of cognitive dysfunction, although the underlying mechanisms remain unclear. We will employ a combination of 256-lead high-density electroencephalography, multimodal magnetic resonance imaging, and biological samples to conduct a comprehensive evaluation of the risk factors associated with cognitive decline in patients with MMD. Our objectives include identifying target imaging areas indicative of cognitive damage in the brain and exploring the structural and functional changes in the cerebral network resulting from revascularization, as well as their relationship with cognitive improvement.

03

Conditions studied

  • Moyamoya Disease

Keywords

  • Cognitive Impairment
  • Moyamoya Disease
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Consecutive patients diagnosed with MMD in Beijing Tiantan Hospital will be recruited. Eligibility will be determined through a checklist of inclusion and exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The admission cerebral angiography (DSA) examination fulfills the diagnostic criteria for moyamoya disease.
  • Please sign the form.
  • Participants must be between 18 and 60 years of age.

Exclusion criteria

Exclusion Criteria:

  • Patients with concurrent atherosclerosis, diseases, meningitis, brain tumors, Down syndrome, craniocerebral trauma, prior radioactive head irradiation, or hyperthyroidism, which may result in secondary cerebrovascular lesions leading to symptoms associated with smoke syndrome.
  • Individuals younger than 18 years or older than 60 years.
  • Those with for magnetic resonance imaging.
  • Patients who are unable to complete cognitive brain assessments
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
360 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Interventions

  • ProcedureRevascularization

    Revascularization

06

What researchers measure

Primary outcomes

  1. Change in composite score of neurocognitive function at 6 months after treatment.

    The composite score of neurocognitive function, including Weschsler Adult Intelligence Scale-4th Edition (WAIS-IV), MATRICS Consensus Cognitive Battery (MCCB), Montreal Cognitive Assessment (MoCA), Auditory Verbal Learning Test (AVLT), Rey-Osterrieth complex figure (ROCF), Trail Making Test (TMT), Stroop test, Verbal Fluency Test (VFT), and Boston Naming Test (BNT) will be collected before and 6 months after treatment.

    Time frame: 6 months during follow-up

Secondary outcomes

  1. Changes in composite score of neurocognitive function at 12 and 24 months after treatment.

    The composite score of neurocognitive function, including Weschsler Adult Intelligence Scale-4th Edition (WAIS-IV), MATRICS Consensus Cognitive Battery (MCCB), Montreal Cognitive Assessment (MoCA), Auditory Verbal Learning Test (AVLT), Rey-Osterrieth complex figure (ROCF), Trail Making Test (TMT), Stroop test, Verbal Fluency Test (VFT), and Boston Naming Test (BNT) will be collected before and 12 and 24 months after treatment.

    Time frame: 12 and 24 months during follow-up

  2. Rate of participants experiencing cerebrovascular events (TIA, infarction and hemorrhage) within 6, 12 and 24 months after treatment.

    Time frame: 6, 12 and 24 months during follow-up

  3. Changes in neurological function assessed by modified Rankin scale (mRS) at 6, 12, and 24 months following treatment.

    Time frame: 6, 12 and 24 months during follow-up

  4. Changes in neurological function assessed by National Institute of Health stroke scale (NIHSS) at 6, 12, and 24 months following treatment.

    Time frame: 6, 12 and 24 months during follow-up

  5. Changes in cerebral blood perfusion assessed by arterial spin labeling (ASL) at 6, 12, and 24 months after treatment.

    Time frame: 6, 12 and 24 months during follow-up

  6. Hemodynamic changes at the terminal segment of internal carotid artery assessed by computational fluid dynamics (CFD) at 6, 12, and 24 months after treatment.

    Time frame: 6, 12 and 24 months during follow-up

  7. Morphological changes at the terminal segment of internal carotid artery and middle cerebral artery wall assessed by high-resolution vessel wall imaging at 6, 12, and 24 months after treatment.

    Time frame: 6, 12 and 24 months during follow-up

  8. Changes in Power Spectral Density (PSD) assessed by electroencephalography (EEG) at 6, 12, and 24 months after treatment will be measured.

    Time frame: 6, 12 and 24 months during follow-up

  9. Changes in Phase Locking Value (PLV) assessed by electroencephalogram (EEG) at 6, 12, and 24 months after treatment will be measured.

    Time frame: 6, 12 and 24 months during follow-up

  10. Changes in Phase-Lag Index (PLI) assessed by electroencephalogram (EEG) at 6, 12, and 24 months after treatment will be measured.

    Time frame: 6, 12 and 24 months during follow-up

  11. Changes in Degree Centrality assessed by multimodal MRI at 6, 12, and 24 months after treatment.

    Time frame: 6, 12 and 24 months during follow-up

  12. Changes in Clustering Coefficient assessed by multimodal MRI at 6, 12, and 24 months after treatment.

    Time frame: 6, 12 and 24 months during follow-up

  13. Changes in Structural Connectivity Strength assessed by multimodal MRI at 6, 12, and 24 months after treatment.

    Time frame: 6, 12 and 24 months during follow-up

  14. Changes in Network Density assessed by multimodal MRI at 6, 12, and 24 months after treatment.

    Time frame: 6, 12 and 24 months during follow-up

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2025
First posted
Feb 18, 2025
StartActual
Dec 16, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2027
Last update
Feb 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06832839
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Dec 16, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 18, 2025

Study contacts

Qian Zhang, MD
Contact
zhangqianchina@yahoo.com
8613120012579
Chaofan Zeng, MD
Contact
zchf723@163.com
8613693276138

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion